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Available online 24 May 2016Introduction: The inﬂammatory receptor Toll-like receptors (TLRs) activation could induce endothelial inﬂamma-
tory responses, which plays an important role in the development ofmanydiseases including atherosclerosis.We
already found that TLR2 activation of Peptidoglycan (PGN) stimulation could increase intercellular adhesion
molecule-1 (ICAM-1) expression in HCAECs. Since anti-inﬂammatory cytokine interleukin (IL)-37 exhibits
intra- and extracellular properties for suppressing innate inﬂammation, we want to investigate whether IL-37
suppresses ICAM-1 expression and this effect is in parallel with the inhibition of nuclear factor kappa B
(NF-κB) activation upon PGN stimulation in HCAECs.
Methods: HCAECs were treated with IL-37-transfection plasmid or silent mRNA or nothing for 24 h, and we
test IL-37 expression by immunoblotting. Same treatments prior to PGN stimulation (10 μg/ml), we ana-
lyzed the expression of ICAM-1 and NF-κB mRNA at 0, 30 min, 1 and 2 h by real-time PCR. ICAM-1 protein
at 24 h and NF-κB activation at 0–2 h were measured by immunoblotting.
Results: IL-37 and silent IL-37 transfection change the expression of IL-37 protein. Stimulation of PGN in-
creased both NF-κB activation and ICAM-1 expression at mRNA and protein level, but these inﬂammatory
cytokines’ expression was signiﬁcantly decreased in IL-37-transfection cells. Interestingly, both NF-κB acti-
vation and ICAM-1 expression were signiﬁcantly increased when IL-37 was silent.
Conclusions: As an anti-inﬂammatory cytokine, IL-37 could decrease both NF-κB and ICAM-1 expression
upon TLR2 activation in HCAECs. The suppressed effect of IL-37 on ICAM-1 may be due to its inhibition on
NF-κB.







IL-37 is already considered as a fundamental inhibitor with intra-
and extracellular properties for suppressing innate inﬂammation [1,2].
It is already proved to be involved in the systematic inﬂammatory dis-
eases such as rheumatoid arthritis, atherosclerotic diseases and some
others [3–6]. These diseases could be treated when inhibition of pro-
inﬂammatory cytokines by IL-37 [3,7]. Evidence showed that IL-37geon, First Afﬁliated Hospital of
oad, Shantou City, Guangdong
st AfﬁliatedHospital of Shantou
ntou City, Guangdong province
126.com (J. Li).
. This is an open access article underwas expressed in the foam-like cells of atherosclerosis coronary and
carotid artery plaques in IL-37-transgenic mice, suggesting that IL-37
is involved in the formation of atherosclerotic plaque [8]. It is still un-
clear how this factor is involved in the process and the role on the devel-
opment of atherosclerosis.
As an inﬂammatory disease, atherosclerosis is characterized by ex-
tensive lipid deposition and atherosclerotic plaque formation in the in-
tima, which is initiated and enhanced by inﬂammatory responses of
endothelial cells. Endothelial dysfunction caused by inﬂammation is a
key initiating event in atherosclerotic plaque formation. [9,10]. Some
studies already found that IL-37 expression ameliorates inﬂammatory
responses in epithelial cells, macrophages and dendritic cells and psori-
asis disease [1,6,11,12]. It is not determined the role of IL-37 plays in the
inﬂammation of HCAECs. And these studies also indicate that IL-37 pos-
sibly ameliorates the inﬂammation process on the development of ath-
erosclerosis if it can reduce inﬂammatory response in HCAECs.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tors that recognize bacterial and viral products, and other pathogens.
We already found that TLR2/4 stimulations cause inﬂammation in
HCAECs including ICAM-1 and NF-κB [13]. It is already proved that
IL-37 could inhibit innate immune responses upon the stimulation of
TLR4 ligand Lipopolysaccharide (LPS) [14]. In this study, we want to in-
vestigate whether IL-37 could reduce ICAM-1 expression activated by
PGN in HCAECs, and the possible mechanism of inhibition of IL-37 is
in parallel with NF-κB, a key inﬂammatory factor on the TLR2 pathway.
2. Materials and methods
2.1. Materials
HCAECs were purchased from ScienCell Research Laboratories (San
Diego, California, USA). IL-37b plasmid vector with a GFP expression
sequence and silent IL-37 mRNA were produced in Genepharma
(Shanghai, China). Staphylococcus aureus PGN was from Sigma-
Aldrich (St. Louis, MO, USA). The following antibodies were used for
Western-blot analysis: mouse anti-human interleukin 37 (Abcam,
Cambridge, MA, USA), mouse anti-human intercellular adhesion mole-
cule (ICAM)-1 (Abcam, Cambridge, MA, USA), rabbit anti-human NF-κB
p65 (Cell Signaling Technology, Boston, MA, USA), rabbit anti-human
phosphor-NF-κB p65 (Cell Signaling Technology, Boston, MA, USA),
and rabbit anti-human GAPDH (Xianzi Biological Tech, Hangzhou,
China). RNeasy micro kit was purchased from PrimeScript RT Master
Mix (TAKARA Bio, Dalian, China).
2.2. Culture of human HCAECs
Cells were grown in endothelial cell growth medium (ECM from
ScienCell, San Diego, California, USA). For the experiments, cells were
seeded in 1 ml complete medium in 12-well plates. After growing to
conﬂuence, mediumwas changed completely. PGNwas diluted in com-
plete cell culturemediumand added to the cells. The ﬁnal concentration
of PGNwas10 μg/ml. For IL-37b transfection or silence, HCAECswere in-
cubated with IL-37b or silent IL-37 plasmid (ﬁnal concentrations were
1.0 μg/ml or 40 pmol/ml, respectively) using the Lipofectamine® 3000
(Invitrogen Life Technology, Shanghai, China), followed by a 24 hour
recovery.
2.3. Immunoblotting
Immunoblotting was used to detect IL-37, ICAM-1, phosphorylated
NF-κB p65, and GAPDH. After treatment, HCAECs were washed
three times with cold PBS, and then lysed with lysis buffer (protease
inhibitor cocktail and Mammalian Protein Extraction Reagent, Ther-
mo Scientiﬁc, Waltham, MA, USA). Samples were separated on 10%
SDS-polyacrylamide gels and transferred onto polyvinyl mem-
branes. Membranes were blocked for 1 h at room temperature with
10% dry milk in TBST (TBS containing 0.1% Tween 20) and then incu-
bated with the appropriate primary antibodies (IL-37 antibody was
diluted into 1:500, ICAM-1 1:1000, Phosphor-NF-κB p65 1:1000,Fig. 1. HCAECs were treated with IL-37-transfection plasmid or silent mRNA for 24 h. IL-37 pro
cells while decreased in silent group compared to control.GAPDH 1:1000) overnight at 4 °C. After washing with TBST, mem-
branes were incubated with Alkaline phosphatase-linked secondary
antibodies (1:4000 dilution with TBST) at room temperature for 1 h.
Bands were developed using ECL and exposed on X-ray ﬁlms. Band
density was analyzed using NIH Image software.
2.4. RNA isolation and real-time PCR
Conﬂuent HCAECs were pre-treated with IL-37b or silent IL-37 plas-
mid for 24 h, and then treated with or without PGN. Thereafter cells
were harvested with TRIzol reagent (Life Technologies, Shanghai,
China) according to the manufacturer's instructions. cDNA was pre-
pared by reverse transcription. Real-time PCR was performed using
CFX Connect Real-Time System (Applied BIO-RAD, Hercules, California,
USA) and SYBR Premix Ex Taq (Tli RNaseH Plus) (TAKARA Bio, Dalian,
China). Each reaction was carried out for a total volume of 25 μl
(12.5 μl SYBR Premix Ex Taq (Tli RNaseH Plus) (2×), 1 μl PCR Forward
Primer, 1 μl PCR Reverse Primer, 2.0 μl of synthesized cDNA, and 8.5 μl
dH2O). Reaction mixtures were heated to 95 °C for 30 s, followed by
40 cycles of denaturation at 95 °C for 5 s, and annealing extension at
60 °C for 30 s. The following sets of primers were used to amplify specif-
ic cDNA fragments: GAPDH (house-keeping gene), forward: 5′-CTG
GGA GGA GAA GAT GC; reverse: 5′-ACC TTT GTT CCA CGA CCC ATA
GC-3′; ICAM-1, forward: 5′-AGC TTC TCC TGC TCT GCA AC; reverse:
5′-GTC TGC TGG GAA TTT TCT GG; NF-κB p65-1, forward: 5′-GCG AGA
GGA GCA ACA GAT ACC; reverse: AGG GGT TGT TGT TGG TCT GGC.
2.5. Statistics
Data are expressed as mean ± standard error of mean (SEM).
Analysis of variance (ANOVA) was performed, and differences were
considered signiﬁcant when P b 0.05, as veriﬁed by Fisher post-hoc test.
3. Results
3.1. Expression of IL-37 reduce PGN-induced ICAM-1 production in
endothelial cells
The expression of IL-37 protein was signiﬁcantly increased in IL-37-
transfection cells and signiﬁcantly decreased when IL-37 was silent
(Fig. 1). PGN increased NF-κB activation and ICAM-1 levels in HCAECs
[13]. We examined the effect of IL-37 on ICAM-1 levels in cell lysate of
HCAECs exposed to PGN by immunoblotting. Fig. 2 shows that PGN in-
creased ICAM-1 protein production, and this effect was markedly re-
duced in IL-37 transfected HCAECs. Furthermore, silence of IL-37 could
not reduce PGN-induced ICAM-1 levels. To conﬁrm the effect of IL-37
on ICAM-1, we also analyzed ICAM-1 mRNA at 0, 30 min, 1 h and 2 h
by real-time PCR (Fig. 3). The results show that ICAM-1mRNAmarkedly
decreased in IL-37 plasmid group compared to control group at 1 h and
2 h (P b 0.05). Interestingly, silence of IL-37 could increase ICAM-1
mRNA and protein production if compared to control when TLR2 ac-
tivation (P b 0.05). These results indicate IL-37 could suppress PGN-
mediated inﬂammatory responses in endothelial cells.tein levels were analyzed by immunoblotting. IL-37 protein increased in IL-37 transfected
Fig. 2. Expression of IL-37 reduces ICAM-1 protein in HCAECs following TLR2 stimulation.
24 h prior to the treatment, HCAECswere treatedwith IL-37-transfection plasmid or silent
mRNAor nothing, thenwere stimulatedwith PGN(10 μg/ml) for 24h, and ICAM-1protein
levels were analyzed by immunoblotting. IL-37-transfection cells exhibited a greater
decrease in ICAM-1 protein levels compared to control and silent group.
Fig. 3. Expression of IL-37 reduces ICAM-1mRNA inHCAECs following TLR2 stimulation. 24 h pr
or nothing, thenwere stimulatedwith PGN (10 μg/ml) for 10min, 30min, 1 h and 2 h and analy
levels of ICAM-1mRNA at 1 and 2 h (P b 0.05). The levels of ICAM-1mRNA signiﬁcantly increase
5; *P b 0.05 vs. cells treated with PGN.
Fig. 4. Expression of IL-37 reduces NF-κBmRNA inHCAECs following TLR2 stimulation. 24 h prio
nothing, thenwere stimulatedwith PGN (10 μg/ml) for 10min, 30min, 1 h and 2 h and analyzed
of NF-κBmRNA at 30min, 1 and 2 h (P b 0.05). But the levels of NF-κBmRNA signiﬁcantly incre
n = 5; *P b 0.05 vs. cells treated with PGN.
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endothelial cells
PGN increased ICAM-1 levels dependent on NF-κB activation in
HCAECs [13]. To test whether the suppression effect of IL-37 on ICAM-
1 level is associated with change of NF-κB activation in HCAECs, we ana-
lyzed NF-κB activation at 10min, 30 min, 1 h and 2 h by immunoblotting
(Fig. 5), and NF-κBmRNA by real-time PCR (Fig. 4). It is shown that PGN-
mediatedNF-κBmRNAwasmarkedly reduced at 30min, 1 h and 2h time
point when exposed to IL-37 (P b 0.05), while it was markedly increased
when exposed to silent IL-37 (P b 0.05). And NF-κB protein level was
markedly decreased, while it was also markedly increased when IL-37 si-
lent (Fig. 5). These results indicated that suppression of IL-37 on ICAM-1
production is in parallel with the reduction of NF-κB activation.ior to the treatment, HCAECswere treatedwith IL-37-transfection plasmid or silent mRNA
zed for ICAM-1mRNA levels by real time RT-PCR. IL-37-transfection cells expressed lower
dwhen IL-37was silent at 1 and 2 h (P b 0.05). Results are expressed asMean± SEM; n=
r to the treatment, HCAECswere treatedwith IL-37-transfection plasmid or silentmRNA or
for NF-κBmRNA levels by real time RT-PCR. IL-37-transfection cells expressed lower levels
ased when IL-37 was silent at 1 and 2 h (P b 0.05). Results are expressed asMean± SEM;
Fig. 5. Expression of IL-37 reduces NF-κB activation in HCAECs exposed to TLR2
stimulation. 24 h prior to the treatment, HCAECs were treated with IL-37-transfection
plasmid or silent mRNA or nothing, then were stimulated with PGN (10 μg/ml) for
10 min, 30 min, 1 h and 2 h. NF-κB phosphorylation was analyzed by immunoblotting.
A. NF-κB activation increased in normal cells. B. NF-κB activation didn't markedly
increase in IL-37-transfection cells, especially at 1 and 2 h. C. NF-κB activation
signiﬁcantly increased in silent-IL37-transfection cells.
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In the previous study of HCAECs, we already found that TLR2 activa-
tion could increase inﬂammatory cytokine ICAM-1 and NF-κB expres-
sion [13]. In this study, we ﬁrstly conﬁrm that expression of IL-37 in
HCAECs could be regulated when were treated with IL-37-transfection
plasmid or silent mRNA for 24 h. We found that IL-37, as an anti-
inﬂammatory cytokine, could decrease ICAM-1 and NF-κB expression
mediated by TLR2 activation in HCAECs. But ICAM-1 and NF-κB expres-
sion were increased when IL-37 was knocked out. The present study
shows that IL-37 could effectively decrease inﬂammatory response of
TLR2-NF-κB pathway.
IL-37 is found to have an anti-inﬂammatory function and has been
demonstrated in a variety of cell types from different species, including
in humans and rodents [14,15]. It is not well demonstrated that
inhibited mechanism of IL-37 on inﬂammation both in extra- and in-
tracellular. Previous studies show that intracellular IL-37 can trans-
locate to the nucleus to down-regulate pro-inﬂammatory cytokine
expression [13,16], and extracellular forms of IL-37 utilizes IL-1R8
to exert its effect of inﬂammation inhibition both in vitro and
in vivo [2]. Furthermore, a mutation on the caspase-1 cleavage site
of IL-37 makes it incapable of reducing LPS-induced immuneresponses in IL-37 transfected cells [1]. In the present study on
HCAECs, we found that ICAM-1 and NF-κB expression signiﬁcantly
decreased by overexpression of recombinant IL-37b, while this effect
is not exhibited even abrogatedmarkedly when IL-37mRNA is silent.
We can consider that the effect and mechanism of IL-37 on ICAM-1
expression may be due to the reduction of NF-κB.
TLR activation is associated with an increase in intranuclear NF-κB
phosphorylation. NF-κB is a key transcription factor that translocates
to the nucleus to initiate the transcription of pro-inﬂammatory genes,
so that mediates cellular inﬂammatory response including the expres-
sion of chemokines and cytokines [17]. The activation of NF-κB occurs
through phosphorylation of IκBα by IKKβ and/or phosphorylation of
p100 by IKKα, leading to the degradation of IκBα and/or the processing
of p100 into smaller form (p52). This process allows two forms of acti-
vated NF-κB (p50–p65 and p52-RelB) to become free, resulting in the
translocation of the activated NF-κB into the nucleus for binding to
NF-κB-speciﬁc DNA-binding sites, which, in turn, regulates the tran-
scription of target genes, including ICAM-1 [18]. In this study, we dem-
onstrate the effect of IL-37 on ICAM-1 level by decrease of NF-κB
phosphorylation. But we are not sure whether this effect of IL-37
could inhibit NF-κB phosphorylation directly or decrease upstream reg-
ulatory factors indirectly, such as IκBα, or IKKβ, or IKKα. This needs to
be further explored in the future study.
Another possibility of inhibited effect of IL-37 on ICAM-1 may be in-
dependent on NF-κB phosphorylation, but may be due to the inhibition
of IL-18. IL-18 could increase ICAM-1 expression [19,20], while IL-37
was reported to inhibit IL-18 by enhancing the effect of IL-18BP [15],
so the decreasing effect of IL-37 on ICAM-1 may be through IL-18 path-
way. So far, we can exclude this possibility, and have to make more
studies to make it clear in the future study.
IL-37 is found to exhibit anti-inﬂammation function in a variety of
cell types in humans [14,15]. When this cytokine mRNA was silent,
the present study in HCAECs shows that inﬂammation was signiﬁcantly
enhanced. This should be because anti-inﬂammation function of IL-37
was also exhibited in control, but disappeared in silent group. This result
further conﬁrmed our hypothesis that IL-37 has anti-inﬂammation
function upon TLR2 activation in HCAECs.
Inﬂammatory activation of the endothelial cells is a critical step in
the development ofmanydiseases, including atherosclerotic plaque for-
mation [21–23]. IL-37 was found to ameliorate the inﬂammatory pro-
cess in psoriasis by suppressing proinﬂammatory cytokine production
[11]. Since TLR2 activation can increase ICAM-1 expression [13], the in-
hibition of TLR2-NF-κB-ICAM-1 pathway in HCAECs can signiﬁcantly
decrease the development of many diseases. Present study indicates
that the effect of IL-37 in HCAECsmay improve endothelial dysfunction,
so that control the development of many diseases. And increasing re-
cent studies already conﬁrm the effect and mechanism of this anti-
inﬂammatory cytokine. So how to enhance the effect of IL-37 may be
the next study point in the future.5. Conclusion
In our study, the results of present study in HCAECs show that NF-
κB-ICAM-1 expression upon TLR2 activation could be decreased by IL-
37. The decreasing expression of IL-37 on TLR2-NF-κB-ICAM-1 pathway
in HCAECsmay help to control many diseases including atherosclerosis.Authors' contributions
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